SAN DIEGO, May 31, 2018 (GLOBE NEWSWIRE) -- Samumed, LLC, a leader in Wnt signaling pathway research and development, today announced that it will present clinical and pre-clinical data on its small molecule investigational drugs for the treatment of osteoarthritis (OA), tendinopathy (TEN), and degenerative disc disease (DDD), in five separate abstracts at The Orthobiologic Institute (TOBI) Annual Symposium, to be held June 7-9, 2018 in Las Vegas.
“We are pleased to have the opportunity at TOBI to present data on three separate programs: a potential disease modifying treatment in knee OA, a first-in-class topical treatment for tendinopathy, and a potential regenerative intradiscal injection for DDD,” said Yusuf Yazici, M.D., Chief Medical Officer of Samumed. “TOBI provides an excellent platform for physicians to share and discuss innovative research and treatment options in various orthobiologic approaches and regenerative medicine therapies for musculoskeletal diseases. We look forward to highlighting our unique approach using small molecules.”
Samumed’s abstracts, listed by therapeutic area below, are available for viewing as posters throughout the duration of the meeting:
Experimental Tendinopathy Treatment with SM04755, a Topical Small Molecule Wnt Pathway Inhibitor
Further details can be found on the TOBI website at http://www.prpseminar.com/tobi-2018/. A copy of the presentation materials can be accessed by visiting the Publications section of the Samumed website after the presentations conclude.
About The Orthobiologic Institute
The Orthobiologic Institute (TOBI) was founded to share best practices in biologics and regenerative medicine research and orthopedic applications. TOBI promotes a high-quality, standardized approach to biologic treatments, to advance the field, and gain recognition as viable, effective treatment.
On June 7-9 2018, TOBI will host its 9th PRP & Regenerative Medicine Symposium at Wynn Las Vegas featuring leading experts representing over 40 countries, with a goal of sharing research, as well as promoting standardization and best practice. Faculty from Mayo Clinic, Harvard, Stanford, Wake Forest, Case Western, Emory, and more gather year after year at this meeting.
About SM04690
SM04690 is a small molecule inhibitor of the Wnt pathway administered as an intra-articular injection, and is being developed as a potential disease-modifying drug for osteoarthritis (DMOAD). Preclinical data have suggested SM04690 has a dual mechanism of action with three specific effects on joint health – generation of articular cartilage, slowing down cartilage degradation, and reducing inflammation in the joint. There are currently no approved disease modifying treatments for osteoarthritis. Additional information on Samumed’s SM04690 osteoarthritis program can be found here:
https://www.samumed.com/pipeline/detail.aspx?id=20
SM04690 is also being developed for the treatment of degenerative disc disease. Preclinical data have shown that in a rat model of DDD, a single intradiscal injection of SM04690 initiated regeneration, improved intervertebral disc structure, and improved disc health. Additional information on Samumed’s SM04690 degenerative disc disease program can be found here:
https://www.samumed.com/pipeline/detail.aspx?id=7
About SM04755
SM04755 is a small-molecule Wnt pathway inhibitor and is being developed as a potential topical therapeutic for tendinopathy. Preclinical data have shown that SM04755 may inhibit inflammation, reduce fibrosis, and increase tenocyte differentiation (tendon repair). Additional information on Samumed’s SM04755 tendinopathy program can be found here:
https://www.samumed.com/pipeline/detail.aspx?id=13
About Samumed
Samumed’s small-molecule drug platform is harnessing the innate restorative power of the Wnt pathway to reverse the course of severe and prevalent diseases. Learn more about Samumed’s potential regenerative therapeutics and broad clinical pipeline at https://www.samumed.com/pipeline/default.aspx
Corporate Contact:
Erich Horsley
Samumed, LLC
erich@samumed.com
858-365-0200
Investor Contact:
Ashley Robinson
LifeSci Advisors
arr@lifesciadvisors.com
617-535-7742
Media Contact:
Matt Middleman, M.D.
LifeSci Public Relations
matt@lifescipublicrelations.com
646-627-8384